0001192482-21-000084.txt : 20210121
0001192482-21-000084.hdr.sgml : 20210121
20210121162852
ACCESSION NUMBER: 0001192482-21-000084
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210119
FILED AS OF DATE: 20210121
DATE AS OF CHANGE: 20210121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brannelly Paul
CENTRAL INDEX KEY: 0001394936
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37372
FILM NUMBER: 21542323
MAIL ADDRESS:
STREET 1: C/O KARYOPHARM THERAPEUTICS INC.
STREET 2: 2 MERCER ROAD
CITY: NATICK
STATE: MA
ZIP: 01760
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC
CENTRAL INDEX KEY: 0001267565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: VA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
BUSINESS PHONE: 781-713-3699
MAIL ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
FORMER COMPANY:
FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC
DATE OF NAME CHANGE: 20031020
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2021-01-19
0001267565
COLLEGIUM PHARMACEUTICAL, INC
COLL
0001394936
Brannelly Paul
C/O COLLEGIUM PHARMACEUTICAL, INC.
100 TECHNOLOGY CENTER DRIVE
STOUGHTON
MA
02072
0
1
0
0
Executive Vice President & CFO
Common Stock
2021-01-19
4
A
0
42000
0
A
215758
D
Common Stock
2021-01-19
4
A
0
8161
A
223919
D
Stock Option (Right to Purchase)
24.06
2021-01-19
4
A
0
120000
0
A
2031-01-19
Common Stock
120000
120000
D
Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.
On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 8,161 performance share units granted in two prior years.
Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2022, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer.
/s/ Paul Brannelly
2021-01-21